[
    [
        {
            "time": "2021-08-10",
            "original_text": "贝莱德减持泰格医药(03347)12.2万股，每股作价约152.74港元 减持股份",
            "features": {
                "keywords": [
                    "贝莱德",
                    "减持",
                    "泰格医药",
                    "12.2万股",
                    "152.74港元"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝莱德减持泰格医药(03347)12.2万股，每股作价约152.74港元 减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "泰格医药(03347.HK)委任吴灏为公司联席总裁",
            "features": {
                "keywords": [
                    "泰格医药",
                    "吴灏",
                    "联席总裁"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)委任吴灏为公司联席总裁",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "【权益变动】泰格医药(03347.HK)被贝莱德减持12.2万股 减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "贝莱德",
                    "减持",
                    "12.2万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)被贝莱德减持12.2万股 减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "港股医药外包概念股走弱，维亚生物跌7.4%，方达控股跌5.14%，昭衍新药跌4.3%，泰格医药跌1.8%",
            "features": {
                "keywords": [
                    "港股",
                    "医药外包",
                    "维亚生物",
                    "方达控股",
                    "昭衍新药",
                    "泰格医药"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股医药外包概念股走弱，维亚生物跌7.4%，方达控股跌5.14%，昭衍新药跌4.3%，泰格医药跌1.8%",
                "Correlation": 8,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "神经介入植入医疗器械研发商励楷科技完成数亿元B轮融资，恒旭资本领投",
            "features": {
                "keywords": [
                    "励楷科技",
                    "融资",
                    "恒旭资本",
                    "B轮"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "神经介入植入医疗器械研发商励楷科技完成数亿元B轮融资，恒旭资本领投",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]